Facebook Twitter

Russia’s coronavirus vaccine shows ‘no serious adverse’ effects yet, new study says

The coronavirus vaccine out of Russia is showing positive signs so far despite being only in early trial stages

SHARE Russia’s coronavirus vaccine shows ‘no serious adverse’ effects yet, new study says
In this handout photo taken on Thursday, Aug. 6, 2020, and provided by Russian Direct Investment Fund, a new vaccine is on display at the Nikolai Gamaleya National Center of Epidemiology and Microbiology in Moscow, Russia.

In this handout photo taken on Thursday, Aug. 6, 2020, and provided by Russian Direct Investment Fund, a new vaccine is on display at the Nikolai Gamaleya National Center of Epidemiology and Microbiology in Moscow, Russia.

Associated Press

A new peer-reviewed study in The Lancet has found that Russia’s potential coronavirus vaccine has no major side effects yet.

  • According to The Lancet, doctors in the trials have done two phase one and phase two studies at two hospitals in Russia.
  • The trials included 76 healthy volunteers from 18 to 60 years old.
  • The vaccine formulations were “safe and well tolerated,” the article said.

  • The trials — which lasted 42 days and had 38 adults each — “did not find any serious adverse effects among participants, and confirmed that the vaccine candidates elicit an antibody response,” the study’s authors wrote.
  • “Large, long-term trials including a placebo comparison, and further monitoring are needed to establish the long-term safety and effectiveness of the vaccine for preventing COVID-19 infection.”

What to consider about Russia’s vaccine

Back in August, Russian President Vladimir Putin said the country had the world’s first coronavirus vaccine, as I wrote for Deseret.com. He said he even tested the vaccine on his daughter.

  • “As far as I know, a vaccine against a new coronavirus infection has been registered this morning, for the first time in the world,” he said at a meeting with members of the government, RIA Novosti reported.

But Dr. Scott Gottlieb, the former U.S. Food and Drug Administration commissioner, told CNBC he wouldn’t use the COVID-19 vaccine from Russia unless there was a clinical trial that proved it was successful.

  • “They’ve cleared the equivalent, really, of a phase 1 clinical trial in terms of putting it in 100 to maybe as many as 300 patients so it needs to be evaluated in a large-scale clinical trial.”